ARE YOU 70-79 YEARS OF AGE?

SHINGLES CAN BE SERIOUS

So serious it could lead to severe nerve pain that can last for months, even years.[1]

Hypothetical patient. May not be representative of every patient's experience of shingles.

Other complications of shingles may include:

- **Scarring,**
- **Vision loss (if rash involves the eye),[2]**
- **Increased risk of stroke.[3]**

1 in 3 people may develop shingles in their lifetime, and the risk of developing shingles and related complications increases over the age of 70.[2,4,5]

ASK YOUR DOCTOR ABOUT GOVERNMENT FUNDED PREVENTION AND TREATMENT OPTIONS.

SHINGLES IS UNPREDICTABLE AND CAN STRIKE AT ANYTIME

1 in 3 adults may develop shingles in their lifetime[2]

- 97% of adults have the virus that causes shingles within them.[6]
- The risk of developing shingles increases over the age of 70.

There is no way to predict when shingles will occur or how severe it will be.

Shingles pain can be excruciating and has been described as burning or stabbing[1]

- The pain can disrupt your sleep and everyday life.[2]
- Up to 20% of adults with shingles may develop long term nerve pain which may last months, even years.[1,5]

Other complications of shingles may include:

- Scarring,
- Vision loss (if rash involves the eye),[2]
- Increased risk of stroke.[3]

ASK YOUR DOCTOR ABOUT GOVERNMENT FUNDED PREVENTION AND TREATMENT OPTIONS.

SHINGLES CAN BE SERIOUS

Hypothetical patient. May not be representative of every patient's experience of shingles.

FOR MORE INFORMATION ABOUT SHINGLES TALK TO YOUR DOCTOR OR VISIT WWW.SHINGLES.COM.AU

REFERENCES: 1. Oxman MN *et al. In: Arvin AM et al.*, editors. Varicella-Zoster Virus: Virology and Clinical Management. 2000. p246–75. **2.** Harpaz R *et al. MMRW* 2008 Jun 6; 57(RR-5): 1–30. **3.** Langan SM *et al. Clin Infect Dis.* 2014; 58:1497–1503. **4.** MacIntyre R. *et al. PLoS ONE.* 2015; 10(4):e0125025. **5.** Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook, Australian Government Department of Health, Canberra, 2018. Available at: https://immunisationhandbook.health.gov.au/ Accessed [November 2018]. **6.** Gidding *et al. Epidemiol Infect* 2003;131(3):1085–9.

Seqirus™ is a trademark of the CSL Group. Seqirus (Australia) Pty Ltd. ABN 66 120 398 067, 63 Poplar Road Parkville, Victoria 3052. Date of preparation December 2018. SEQ/ZOST/1118/0353.

Seqirus™
A CSL COMPANY